Advertisement

Intensive Care Medicine

, Volume 42, Issue 10, pp 1639–1640 | Cite as

Elevated soluble IL-7 receptor concentration in non-survivor ICU patients

  • Estelle PeronnetEmail author
  • Julie Mouillaux
  • Guillaume Monneret
  • Emmanuelle Gallet-Gorius
  • Sophie Blein-Henry
  • Alain Lepape
  • Julien Textoris
  • Fabienne Venet
  • the MIP Réa Study Group
Letter

Dear Editor,

Patients admitted to intensive care units (ICU) are prone to immunosuppression, the intensity and duration of which are associated with deleterious outcomes [1]. Currently, therapy such as IL-7 is being tested (NCT02640807) with the intention of restoring immune functions. In this context, and to follow up on a previous study in septic shock patients published in Intensive Care Medicine [2], we further investigated the prognostic value of the soluble form of IL-7 receptor alpha chain (or sCD127) in ICU patients. We confirmed and extended our previous results to ICU patients with systemic inflammatory response syndrome, presenting with various severity levels.

To this end, we measured sCD127 plasmatic concentration with a standardized and robust ELISA assay (Method 1 in the electronic supplementary material), in a cohort of 734 ICU patients [3]. This study was approved by our ethical institutional review board (IRB#5044). Clinical data are described in Tables 1 and 2 of...

Keywords

Intensive Care Unit Patient Septic Shock Patient sCD127 Level Ethical Institutional Review Board Receptor Alpha Chain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors gratefully acknowledge the MIP-Réa study group for their participation in the MIP-Réa clinical study. The authors also would like to thank Hélène Vallin, Nathalie Panel, Marion Provent, and Sylvie De La Salle for their great help in patients’ inclusion and Anne Portier for the clinical samples management. The authors thank Caroline Le Gall from Methodomics for statistical analysis. Funding was provided by the authors’ institutions (Hospices Civils de Lyon and bioMérieux) and was part of ADNA (Advanced Diagnostic for New Therapeutic Approaches), a program dedicated to personalized medicine, coordinated by Institut Mérieux and supported by the French public agency BPI France.

Compliance with ethical standards

Conflicts of interest

All authors work in a joint research unit, co-funded by the Hospices Civils de Lyon and bioMérieux. FV, GM, and AL are co-inventors in two patents families covering soluble CD127 biomarkers. This does not alter the authors’ adherence to all the Intensive Care Medicine policies on sharing data and materials.

Supplementary material

134_2016_4445_MOESM1_ESM.pdf (231 kb)
Supplementary material 1 (PDF 230 kb)

References

  1. 1.
    Landelle C, Lepape A, Voirin N et al (2010) Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 36:1859–1866CrossRefPubMedGoogle Scholar
  2. 2.
    Demaret J, Villars-Méchin A, Lepape A et al (2014) Elevated plasmatic level of soluble IL-7 receptor is associated with increased mortality in septic shock patients. Intensive Care Med 40:1089–1096CrossRefPubMedGoogle Scholar
  3. 3.
    Friggeri A, Cazalis M-A, Pachot A et al (2016) Decreased CX3CR1 messenger RNA expression is an independent molecular biomarker of early and late mortality in critically ill patients. Crit Care 20:204Google Scholar
  4. 4.
    Mazzucchelli R, Durum SK (2007) Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7:144–154CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  • Estelle Peronnet
    • 1
    Email author return OK on get
  • Julie Mouillaux
    • 1
  • Guillaume Monneret
    • 1
    • 2
  • Emmanuelle Gallet-Gorius
    • 1
  • Sophie Blein-Henry
    • 1
  • Alain Lepape
    • 3
  • Julien Textoris
    • 1
  • Fabienne Venet
    • 1
    • 2
  • the MIP Réa Study Group
  1. 1.EA 7426 Hospices Civils de Lyon-bioMérieux-UCBL1 “Pathophysiology of Injury Induced Immunosuppression”, Joint Research UnitGroupement Hospitalier Edouard HerriotLyonFrance
  2. 2.Hospices Civils de Lyon, Immunology LaboratoryGroupement Hospitalier Edouard HerriotLyonFrance
  3. 3.Hospices Civils de Lyon, Intensive Care UnitCentre Hospitalier Lyon SudPierre-Bénite CedexFrance

Personalised recommendations